Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2010 2
2013 1
2014 4
2015 6
2016 2
2017 2
2018 7
2019 7
2020 9
2021 14
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

49 results
Results by year
Filters applied: . Clear all
Page 1
Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts.
Zeidan AM, Boddu PC, Patnaik MM, Bewersdorf JP, Stahl M, Rampal RK, Shallis R, Steensma DP, Savona MR, Sekeres MA, Roboz GJ, DeAngelo DJ, Schuh AC, Padron E, Zeidner JF, Walter RB, Onida F, Fathi A, DeZern A, Hobbs G, Stein EM, Vyas P, Wei AH, Bowen DT, Montesinos P, Griffiths EA, Verma AK, Keyzner A, Bar-Natan M, Navada SC, Kremyanskaya M, Goldberg AD, Al-Kali A, Heaney ML, Nazha A, Salman H, Luger S, Pratz KW, Konig H, Komrokji R, Deininger M, Cirici BX, Bhatt VR, Silverman LR, Erba HP, Fenaux P, Platzbecker U, Santini V, Wang ES, Tallman MS, Stone RM, Mascarenhas J. Zeidan AM, et al. Among authors: zeidner jf. Lancet Haematol. 2020 Aug;7(8):e601-e612. doi: 10.1016/S2352-3026(20)30205-2. Epub 2020 Jun 18. Lancet Haematol. 2020. PMID: 32563283 Free PMC article. Review.
Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML.
Sekeres MA, Watts J, Radinoff A, Sangerman MA, Cerrano M, Lopez PF, Zeidner JF, Campelo MD, Graux C, Liesveld J, Selleslag D, Tzvetkov N, Fram RJ, Zhao D, Bell J, Friedlander S, Faller DV, Adès L. Sekeres MA, et al. Among authors: zeidner jf. Leukemia. 2021 Jul;35(7):2119-2124. doi: 10.1038/s41375-021-01125-4. Epub 2021 Jan 22. Leukemia. 2021. PMID: 33483617 Free PMC article. Clinical Trial. No abstract available.
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML.
Swords RT, Coutre S, Maris MB, Zeidner JF, Foran JM, Cruz J, Erba HP, Berdeja JG, Tam W, Vardhanabhuti S, Pawlikowska-Dobler I, Faessel HM, Dash AB, Sedarati F, Dezube BJ, Faller DV, Savona MR. Swords RT, et al. Among authors: zeidner jf. Blood. 2018 Mar 29;131(13):1415-1424. doi: 10.1182/blood-2017-09-805895. Epub 2018 Jan 18. Blood. 2018. PMID: 29348128 Free PMC article. Clinical Trial.
Immune Checkpoint Inhibitors in AML-A New Frontier.
Thummalapalli R, Knaus HA, Gojo I, Zeidner JF. Thummalapalli R, et al. Among authors: zeidner jf. Curr Cancer Drug Targets. 2020;20(7):545-557. doi: 10.2174/1568009620666200421081455. Curr Cancer Drug Targets. 2020. PMID: 32316893 Review.
CD123-targeted therapy in acute myeloid leukemia.
Espinoza-Gutarra MR, Green SD, Zeidner JF, Konig H. Espinoza-Gutarra MR, et al. Among authors: zeidner jf. Expert Rev Hematol. 2021 Jun;14(6):561-576. doi: 10.1080/17474086.2021.1935855. Epub 2021 Jun 14. Expert Rev Hematol. 2021. PMID: 34043467
49 results